AQC-Pattern Accordion-Collapse Accordion-Expand Agenda-Map CROs Consulting Download Email Fax Filter-Check Filter-Remove LinkedIn Map-Pin Member-Login Pharma-Biotech-Devices Phone Summit-Registration Survey-Research The-Avoca-Group-Consulting-And-Research-Services-Horizontal The-Avoca-Group-Diligent-Prequalification-Platform-Horizontal The-Avoca-Group-Quality-Consortium-Horizontal Training avoca-logo-coloravoca-logo-graycheckconsulting_logo2 diligent_logo2 dots dotted-01 dotted down-arrow GroupCreated with Sketch. minus plus quality_logo2 right-arrow twitter
Clinical Trial Optimization Podcast

Twin Peaks — Measurements & Goals: Pros and Cons of Using High-Level Portfolio Milestone Timeliness Metrics with Linda Sullivan and Keith Dorricott


How can you best measure whether vendors are meeting study milestone goals? That’s one of the important issues discussed in Keith Dorricott’s interview with Linda Sullivan, MBA, Executive Director of WCG’s Metric Champion Consortium (MCC). Dorricott is a Director at Dorricott Metrics & Process Improvement Ltd in the UK and facilitates many MCC metric development and community of practice groups. Timeliness metrics — measurements that assess whether study milestones are achieved by their target dates —- are valuable but don’t always tell the entire story, according to Sullivan and Dorricott, such as whether the milestone dates are realistic and how on-time measurements influence human behavior. Then, when you move from measuring a single study to cross-studies or portfolio level, aggregation of data can get even more complicated. There are many ways to “cut” the data, they note, depending on the performance questions you want answered. With timeliness, Dorricott says, it always comes back to expectations — and whether those expectations are reasonable. In this respect, measuring how long it takes to achieve milestones is important and should be reviewed to determine if timeliness expectations are achievable. In terms of rolled-up data, it’s easy to aggregate results across studies but it’s important to determine which studies or process steps are not meeting expectations and need attention. When you aggregate results from a large number of studies, it can be challenging to see when you have a few studies that are not performing well. For this reason, the MCC Vendor Oversight Metric Toolkit includes several portfolio-level milestone timeliness metrics that answer difference performance questions, such as what the overall performance of the portfolio is in terms of milestones met across active studies, performance over the last 3 months and performance reported by study phase.

Subscribe today!

Apple Podcasts Spotify Stitcher Android